{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:29:29Z","timestamp":1772252969169,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Vaccination is considered the most important measure to control the COVID-19 pandemic. Extensive follow-up studies with distinct vaccines and populations are able to promote robust and reliable data to better understand the effectiveness of this pharmacologic strategy. In this sense, we present data regarding binding and neutralizing (achieved by surrogate ELISA assay) antibodies throughout time, from vaccinated and previously infected (PI) health care workers (HCW) in Portugal. We analyzed serum samples of 132 HCW, who were vaccinated and with previous SARS-CoV-2 infection. Samples were collected before vaccination (baseline, M1), at second dose vaccine uptake (M2), and 25\u201370 days (M3) and 150\u2013210 days (M4) after the second dose for vaccinated individuals. The IgG (anti-RBD\/S) antibody geometric mean titers found on vaccinated HCW at M2 (GM = 116.1 BAU\/mL; CI: 92.3\u2013146.1) were significantly higher than those found on PI HCW at recruitment (M1) (GM = 35.9 BAU\/mL; CI:15.4\u201383.4), and the neutralizing antibodies (nAb) were similar between these groups, of 93.2 UI\/mL (95% CI 73.2\u2013118.5) vs. 84.1 UI\/mL (95% CI 40.4\u2013155.9), respectively. We detected around 10-fold higher IgG (anti-RBD\/S) antibodies titers in M3 when compared with M2, with a slight but significant decrease in titers from 36 days after the second dose vaccine uptake. The increase of nAb titers was correlated with IgG (anti-RBD\/S) antibodies titers; however, in contrast to IgG (anti-RBD\/S) antibodies titers, we did not detect a decrease in the nAb titer 36 days after a second vaccine dose uptake. At M4, a decrease of 8-fold in binding IgG (anti-RBD\/S) and nAb was observed. No significant differences in antibody titers were observed by sex, age or chronic diseases. Our results suggest that IgG (anti-RBD\/S) antibodies titers and nAb titers could be correlated, but an ongoing follow up of the cohort is required to better understand this correlation, and the duration of the immune response.<\/jats:p>","DOI":"10.3390\/vaccines10020154","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T22:59:57Z","timestamp":1642719597000},"page":"154","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination"],"prefix":"10.3390","volume":"10","author":[{"given":"Raquel","family":"Guiomar","sequence":"first","affiliation":[{"name":"National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal"}]},{"given":"Ana Jo\u00e3o","family":"Santos","sequence":"additional","affiliation":[{"name":"Epidemiology Department, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6655-8715","authenticated-orcid":false,"given":"Aryse Martins","family":"Melo","sequence":"additional","affiliation":[{"name":"National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal"}]},{"given":"In\u00eas","family":"Costa","sequence":"additional","affiliation":[{"name":"National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal"}]},{"given":"Rita","family":"Matos","sequence":"additional","affiliation":[{"name":"Immunology Laboratory for Infectious Diseases, Infectious Diseases Department, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal"}]},{"given":"Ana Paula","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Epidemiology Department, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5772-2416","authenticated-orcid":false,"given":"Irina","family":"Kislaya","sequence":"additional","affiliation":[{"name":"Epidemiology Department, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal"}]},{"given":"Anabela Santos","family":"Silva","sequence":"additional","affiliation":[{"name":"COVID-19 Working Group, National Institute of Health Doutor Ricardo Jorge, 4000-055 Porto, Portugal"}]},{"given":"Carla","family":"Roque","sequence":"additional","affiliation":[{"name":"Occupational Health Department, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal"}]},{"given":"Carla","family":"Nunes","sequence":"additional","affiliation":[{"name":"COVID-19 Working Group, National Institute of Health Doutor Ricardo Jorge, 4000-055 Porto, Portugal"}]},{"given":"Joaquim","family":"Aguiar","sequence":"additional","affiliation":[{"name":"COVID-19 Working Group, National Institute of Health Doutor Ricardo Jorge, 4000-055 Porto, Portugal"}]},{"given":"F\u00e1tima","family":"Gra\u00e7a","sequence":"additional","affiliation":[{"name":"COVID-19 Working Group, National Institute of Health Doutor Ricardo Jorge, 4000-055 Porto, Portugal"}]},{"given":"Ant\u00f4nio","family":"Silva Gra\u00e7a","sequence":"additional","affiliation":[{"name":"Occupational Health Department, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal"}]},{"given":"Ausenda","family":"Machado","sequence":"additional","affiliation":[{"name":"Epidemiology Department, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"ref_1","unstructured":"WHO (2021). Evaluation of COVID-19 Vaccine Effectiveness, WHO."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 vaccines: Where we stand and challenges ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_3","unstructured":"(2021, October 20). Infarmed Infarmed COVID-19 -Vacinas Aprovadas (Quadro Resumo) 2021. Available online: https:\/\/www.infarmed.pt\/web\/infarmed\/vacinas-aprovadas."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2020.10.108","article-title":"Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity","volume":"538","author":"Carrillo","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"657711","DOI":"10.3389\/fimmu.2021.657711","article-title":"Mini Review Immunological Consequences of Immunization with COVID-19 mRNA Vaccines: Preliminary Results","volume":"12","author":"Lombardi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gobbi, F., Buonfrate, D., Moro, L., Rodari, P., Piubelli, C., Caldrer, S., Riccetti, S., Sinigaglia, A., and Barzon, L. (2021). Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses, 13.","DOI":"10.3390\/v13030422"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Doba\u00f1o, C., Ram\u00edrez-Morros, A., Alonso, S., Vidal-Alaball, J., Ruiz-Olalla, G., Vidal, M., Rubio, R., Cascant, E., Parras, D., and Melero, N.R. (2021). Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. BMC Med., 19.","DOI":"10.1186\/s12916-021-02032-2"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1002\/jmv.26982","article-title":"Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection","volume":"93","author":"Callegaro","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","article-title":"Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals","volume":"397","author":"Manisty","year":"2021","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for COVID-19","volume":"384","author":"Suthar","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1038\/s41467-020-18848-0","article-title":"SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden","volume":"11","author":"Rudberg","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_13","unstructured":"(2021, May 21). Dire\u00e7\u00e3o-Geral da Sa\u00fade Norma No. 002\/2021 de 30\/01\/2021 atualizada a 21\/04\/2021. Available online: https:\/\/backoffice.ump.pt\/files\/files\/norma%20002.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nat. Med."},{"key":"ref_15","unstructured":"Rodrigues, A.P., and Garcia, A.C. (2021). Inqu\u00e9rito Serol\u00f3gico Nacional Relat\u00f3rio de Apresenta\u00e7\u00e3o, Instituto Nacional de Sa\u00fade Dr. Ricardo Jorge."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1001\/jama.2020.8259","article-title":"Interpreting Diagnostic Tests for SARS-CoV-2","volume":"323","author":"Sethuraman","year":"2020","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/all.14364","article-title":"Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19","volume":"75","author":"Azkur","year":"2020","journal-title":"Allergy"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wisnewski, A.V., Campillo Luna, J., and Redlich, C.A. (2021). Human IgG and IgA responses to COVID-19 mRNA vaccines. PLoS ONE, 16.","DOI":"10.1101\/2021.03.23.21254060"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1056\/NEJMoa2106599","article-title":"Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel","volume":"385","author":"Pilishvili","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Andrews","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","unstructured":"ECDC (2021). SARS-CoV-2 Variants of Concern as of 23 September 2021, ECDC."},{"key":"ref_23","first-page":"2016","article-title":"Neutralizing Activity of BNT162b2-Elicited Serum","volume":"69","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMc2106083","article-title":"BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants","volume":"385","author":"Liu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","unstructured":"Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (2021). Diversidade Gen\u00e9tica do Novo Coronav\u00edrus SARS-CoV-2 (COVID-19) em Portugal, Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2100833","DOI":"10.2807\/1560-7917.ES.2021.26.38.2100833","article-title":"mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: A cohort study based on data linkage of national health registries in Portugal, February to August 2021","volume":"26","author":"Nunes","year":"2021","journal-title":"Eurosurveillance"},{"key":"ref_29","unstructured":"(2021, November 28). World Health Organization Update on Omicron. Available online: https:\/\/www.who.int\/news\/item\/28-11-2021-update-on."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(21)00502-X","article-title":"Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine","volume":"397","author":"Prendecki","year":"2021","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101018","DOI":"10.1016\/j.eclinm.2021.101018","article-title":"Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals","volume":"38","author":"Demonbreun","year":"2021","journal-title":"EClinicalmedicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"ref_33","first-page":"811","article-title":"Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years","volume":"818","author":"Wagner","year":"2020","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Chan, K.-H., Leung, K.-Y., Zhang, R.-R., Liu, D., Fan, Y., Chen, H., Yuen, K.-Y., and Hung, I.F.-N. (2021). Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples. Diagnostics, 11.","DOI":"10.3390\/diagnostics11101757"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kohmer, N., R\u00fchl, C., Ciesek, S., and Rabenau, H. (2021). Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies. J. Clin. Med., 10.","DOI":"10.3390\/jcm10102128"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1080\/22221751.2020.1835448","article-title":"Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)","volume":"9","author":"Meyer","year":"2020","journal-title":"Emerg. Microbes Infect."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/154\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:04:51Z","timestamp":1760133891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["vaccines10020154"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10020154","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.10.21267607","asserted-by":"object"}]},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]}}}